The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome

Department of Research, Veterans Administration Boston Healthcare, West Roxbury, MA, USA.
Blood (Impact Factor: 10.45). 11/2009; 115(14):2827-34. DOI: 10.1182/blood-2009-03-211045
Source: PubMed


Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecular events responsible for myelomagenesis remain uncharacterized. To identify cellular pathways deregulated in MM, we addressed that sumoylation is homologous to ubiquitination and results in the attachment of the ubiquitin-like protein Sumo onto target proteins. Sumoylation was markedly enhanced in MM patient lysates compared with normal plasma cells and expression profiling indicated a relative induction of sumoylation pathway genes. The Sumo-conjugating enzyme Ube2I, the Sumo-ligase PIAS1, and the Sumo-inducer ARF were elevated in MM patient samples and cell lines. Survival correlated with expression because 80% of patients with low UBE2I and PIAS1 were living 6 years after transplantation, whereas only 45% of patients with high expression survived 6 years. UBE2I encodes the sole Sumo-conjugating enzyme in mammalian cells and cells transfected with a dominant-negative sumoylation-deficient UBE2I mutant exhibited decreased survival after radiation exposure, impaired adhesion to bone marrow stroma cell and decreased bone marrow stroma cell-induced proliferation. UBE2I confers cells with multiple advantages to promote tumorigenesis and predicts decreased survival when combined with PIAS1. The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies.

Download full-text


Available from: Dheeraj Pelluru, Jan 10, 2014
  • Source
    • "For instance, SUMOylation inhibits cancer establishment through stabilization of tumor suppressor genes or promotes cancer development through stabilization of oncogenes [15,35–43]. Because it is also involved in cellular processes that preserve genomic integrity, such as DNA damage repair, it is thought that aberrancies in SUMOylation possess the ability to promote progression and dissemination, and to initiate therapeutic resistance in cancer cells [44] [45] [46] [47] [48] [49]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK(+)) T-cell lymphoma is an aggressive form of cancer that commonly affects children and adolescents. The expression of NPM-ALK chimeric oncogene results from the chromosomal translocation t(2;5)(p23;q35) that causes the fusion of the ALK and NPM genes. This translocation generates the NPM-ALK protein tyrosine kinase that forms the constitutively activated NPM-ALK/NPM-ALK homodimers. In addition, NPM-ALK is structurally associated with wild-type NPM to form NPM/NPM-ALK heterodimers, which can translocate to the nucleus. The mechanisms that sustain the stability of NPM-ALK are not fully understood. SUMOylation is a posttranslational modification that is characterized by the reversible conjugation of small ubiquitin-like modifiers (SUMOs) with target proteins. SUMO competes with ubiquitin for substrate binding and therefore, SUMOylation is believed to protect target proteins from proteasomal degradation. Moreover, SUMOylation contributes to the subcellular distribution of target proteins. Herein, we found that the SUMOylation pathway is deregulated in NPM-ALK(+) T-cell lymphoma cell lines and primary lymphoma tumors from patients. We also identified Lys(24) and Lys(32) within the NPM domain as the sites where NPM-ALK conjugates with SUMO-1 and SUMO-3. Importantly, antagonizing SUMOylation by the SENP1 protease decreased the accumulation of NPM-ALK and suppressed lymphoma cell viability, proliferation, and anchorage-independent colony formation. One possible mechanism for the SENP1-mediated decrease in NPM-ALK levels was the increase in NPM-ALK association with ubiquitin, which facilitates its degradation. Our findings propose a model in which aberrancies in SUMOylation contribute to the pathogenesis of NPM-ALK(+) T-cell lymphoma. Unraveling such pathogenic mechanisms may lead to devising novel strategies to eliminate this aggressive neoplasm.
    Neoplasia (New York, N.Y.) 10/2015; 17(9):742-754. DOI:10.1016/j.neo.2015.09.005 · 4.25 Impact Factor
  • Source
    • "The transcription of many of the genes encoding proteins required for sumoylation or desumoylation is altered in tumour cells (reviewed by Bettermann et al. 2012). Examples include: the SUMO protease, SENP1 which is upregulated in thyroid oncocytic adenocarcinoma and human prostate cancer (Cheng et al. 2006b; Jacques et al. 2005), Ubc9 which is upregulated in a wide range of tumours including lung adenocarcinoma (McDoniels-Silvers et al. 2002), ovarian cancer cells (Mo et al. 2005), melanoma-infiltrated lymph nodes, and head and neck cancers (reviewed by Mo and Moschos 2005), and the SUMO ligases PIAS1 where mRNA levels are increased in human prostate cancer (Hoefer et al. 2012) and multiple myeloma (Driscoll et al. 2010) and PIAS3, where levels are increased in breast, lung, prostate, colorectal and brain tumours (Wang and Banerjee 2004). Whether the increased transcription is a result of the transformation or contributes to the cause remains to be determined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A large number of proteins are modified post-translationally by the ubiquitin-like protein (Ubl) SUMO. This process, known as sumoylation, regulates the function, localisation and activity of target proteins as part of normal cellular metabolism, e.g., during development, and through the cell cycle, as well as in response to a range of stresses. In order to be effective, the sumoylation pathway itself must also be regulated. This review describes how the SUMOylation process is regulated. In particular, regulation of the SUMO conjugation and deconjugation machinery at the level of transcription and by post-translational modifications is discussed.
    Chromosoma 06/2013; 122(6). DOI:10.1007/s00412-013-0422-0 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, a new structure of sector split-drain MAGFET, based on CSMC standard 0.6 μm N-well CMOS technology, is suggested and its model is also developed. The relationship of its relative sensitivity with device geometry parameters is obtained by computer simulation. A maximum sensor sensitivity of 3.77%/T is obtained in experimental results with an offset value lower than 0.27%. Improvement of sensitivity is attributed to the sector structure.
    Solid-State and Integrated Circuits Technology, 2004. Proceedings. 7th International Conference on; 11/2004
Show more